ALNYLAM PHARMACEUTICALS, INC. Quarterly Nonoperating Income (Expense) in USD from Q1 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Alnylam Pharmaceuticals, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2010 to Q2 2024.
  • Alnylam Pharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was -$59.8M, a 34.7% decline year-over-year.
  • Alnylam Pharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was -$164M, a 29.5% increase year-over-year.
  • Alnylam Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2023 was -$151M, a 55.7% increase from 2022.
  • Alnylam Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2022 was -$342M, a 138% decline from 2021.
  • Alnylam Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2021 was -$143M, a 428% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$164M -$59.8M -$15.4M -34.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 -$149M -$20.2M +$2.4M +10.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 -$151M -$21.3M -$2.88M -15.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-15
Q3 2023 -$148M -$63.1M +$84.8M +57.3% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 -$233M -$44.4M +$38.6M +46.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 -$272M -$22.6M +$70.1M +75.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 -$342M -$18.4M +$47.3M +72% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-15
Q3 2022 -$389M -$148M -$125M -556% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$264M -$83M -$40.8M -96.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$223M -$92.6M -$79.6M -611% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$143M -$65.7M -$16.4M -33.1% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-15
Q3 2021 -$127M -$22.6M +$4.69M +17.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-27
Q2 2021 -$132M -$42.2M -$63.1M -301% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-28
Q1 2021 -$68.7M -$13M -$41.5M -146% Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-28
Q4 2020 -$27.2M -$49.4M -$70.9M -330% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-23
Q3 2020 $43.7M -$27.3M -$34.6M -470% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-28
Q2 2020 $78.3M $21M +$3.21M +18.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $75.1M $28.5M +$20.9M +277% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-29
Q4 2019 $54.2M $21.5M +$12.2M +132% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-10
Q3 2019 $42M $7.37M -$2.35M -24.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $44.3M $17.8M -$11.1M -38.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $55.4M $7.57M +$1.44M +23.5% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q4 2018 $54M $9.28M +$4.2M +82.7% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-11
Q3 2018 $49.8M $9.72M +$6.86M +240% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-31
Q2 2018 $42.9M $28.9M +$26.8M +1306% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $16.1M $6.13M +$6.91M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2017 $9.21M $5.08M +$2.58M +103% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-13
Q3 2017 $6.64M $2.86M +$258K +9.9% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $6.38M $2.05M -$267K -11.5% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $6.65M -$779K -$7.83M -111% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-04
Q4 2016 $14.5M $2.5M +$708K +39.5% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-14
Q3 2016 $13.8M $2.61M +$1.07M +69.4% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 $12.7M $2.32M +$729K +45.8% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $12M $7.05M +$6.04M +596% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-05
Q4 2015 $5.94M $1.79M -$441K -19.8% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-15
Q3 2015 $6.38M $1.54M +$261K +20.4% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-03
Q2 2015 $6.12M $1.59M +$976K +158% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-04
Q1 2015 $5.14M $1.01M +$763K +304% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-04
Q4 2014 $4.38M $2.23M +$1.98M +772% Oct 1, 2014 Dec 31, 2014 10-K 2017-02-15
Q3 2014 $2.4M $1.28M +$999K +359% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-09
Q2 2014 $1.4M $616K +$357K +138% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-07
Q1 2014 $1.04M $251K +$22K +9.61% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-08
Q4 2013 $1.02M $256K -$15.3M -98.4% Oct 1, 2013 Dec 31, 2013 10-K 2016-02-12
Q3 2013 $16.4M $278K +$1.63M Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-06
Q2 2013 $14.7M $259K +$1.15M Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-08
Q1 2013 $13.6M $229K +$704K Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-09
Q4 2012 $12.9M $15.6M +$16.3M Oct 1, 2012 Dec 31, 2012 10-K 2015-02-13
Q3 2012 -$3.44M -$1.36M -$556K -69.6% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-07
Q2 2012 -$2.88M -$889K -$183K -25.9% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-09
Q1 2012 -$2.7M -$475K +$134K +22% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-07
Q4 2011 -$2.83M -$717K -$6.62M -112% Oct 1, 2011 Dec 31, 2011 10-K 2014-02-20
Q3 2011 $3.79M -$799K -$195K -32.3% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-05
Q2 2011 $3.99M -$706K +$2.53M +78.2% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-08
Q1 2011 $1.46M -$609K +$390K +39% Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-03
Q4 2010 $1.07M $5.91M Oct 1, 2010 Dec 31, 2010 10-K 2013-02-19
Q3 2010 -$604K Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-03
Q2 2010 -$3.24M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-03
Q1 2010 -$999K Jan 1, 2010 Mar 31, 2010 10-Q 2011-05-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.